Page 11 - reflections_dyslipidaemia_newsletter5_2023
P. 11

REFLECTIONS
                                                                                                                   Dyslipidaemia
     Dyslipidaemia Global Newsletter #6 2023



     CONFERENCE CORNER                                                                                             Dyslipidaemia


     The ESC Congress, hosted in Amsterdam in Aug 25–28, 2023, is the annual meeting of the European Society of Cardiology.
     We present below some abstracts of interest that may have an impact on clinical practice. Please click on the links to explore the
     abstracts in more detail.



          1. Contribution of lipoprotein(a) to polygenic risk of coronary artery disease: A
            prospective UK Biobank analysis. Arsenault B, et al.


          2. Can the association between LDL-cholesterol and incident coronary heart disease
            (CHD) be modulated by concomitant Lp(a) levels in the general population?
            Arnold N, et al.

          3. Attainment of LDL-cholesterol goals in patients with previous myocardial
            infarction: A real-world cross-sectional analysis. Gomes D, et al.

          4. Survey on lipid management in cardiovascular primary prevention: Do physicians
            follow the guidelines?
            Alami M, et al.


          5. Improving statins effectiveness by targeting baseline LDL cholesterol in type 2 diabetes mellitus, a systematic
            review and meta-analysis. Soroush N, et al.

          6. Moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy according
            to baseline LDL-C levels: A prespecified subgroup analysis of RACING Trial. Lee B, et al.

          7. Strike early and strike strong: Application of a strategy comprising first-line combination of high-intensity statins
            and ezetimibe for patients with acute myocardial infarction in routine practice. Schiele F, et al.

          8. The impact of statin intensity on long-term outcomes in elderly patients with acute myocardial infarction who have
            undergone percutaneous coronary intervention. Choe J, et al.

          9. Cross-sectional analysis of demographic and clinical characteristics of patients using icosapent ethyl.
            Nelson J, et al.

          10. Effectiveness and safety of bempedoic acid in routine clinical practice: 1-year follow-up snapshot of the MILOS
              German cohort. Gouni-Berthold I, et al.





















          TABLE OF CONTENTS
   6   7   8   9   10   11   12   13